Diabetic Kidney Disease Represents a Locus of Opportunity.
作者信息
Ecelbarger Carolyn Mary
机构信息
Department of Medicine/Division of Endocrinology and Metabolism, Georgetown University, Washington, DC, United States.
出版信息
Front Physiol. 2021 Mar 8;12:650503. doi: 10.3389/fphys.2021.650503. eCollection 2021.
Abstract
摘要
相似文献
1
Diabetic Kidney Disease Represents a Locus of Opportunity.
Front Physiol. 2021 Mar 8;12:650503. doi: 10.3389/fphys.2021.650503. eCollection 2021.
2
Diabetic nephropathy: can it be prevented? Are there renal protective antihypertensive drugs of choice?
South Med J. 1994 Oct;87(10):1043-53. doi: 10.1097/00007611-199410000-00017.
3
Systemic hypertension, diabetes mellitus and the kidney.
Am J Cardiol. 1987 Dec 14;60(17):61I-65I. doi: 10.1016/0002-9149(87)90462-0.
4
Concerns about diabetic nephropathy in the treatment of diabetic hypertensive patients.
Am J Med. 1989 Dec 8;87(6A):29S-33S. doi: 10.1016/0002-9343(89)90492-0.
5
Update on Diabetic Nephropathy: Core Curriculum 2018.
Am J Kidney Dis. 2018 Jun;71(6):884-895. doi: 10.1053/j.ajkd.2017.10.026. Epub 2018 Feb 3.
6
Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy.
Ann Pharmacother. 1996 Jul-Aug;30(7-8):791-801. doi: 10.1177/106002809603000718.
7
Diabetic Kidney Disease and Hypertension: A True Love Story.
J Clin Diagn Res. 2016 Mar;10(3):OC11-3. doi: 10.7860/JCDR/2016/18806.7511. Epub 2016 Mar 1.
8
Allograft diabetic nephropathy may progress to end-stage renal disease.
Pediatr Transplant. 2004 Aug;8(4):351-6. doi: 10.1111/j.1399-3046.2004.00182.x.
9
Blood pressure lowering for the prevention and treatment of diabetic kidney disease.
Drugs. 2006;66(17):2213-34. doi: 10.2165/00003495-200666170-00005.
10
Renal protection in diabetes: an emerging role for calcium antagonists.
J Hypertens Suppl. 1996 Nov;14(4):S21-5. doi: 10.1097/00004872-199606234-00005.
本文引用的文献
1
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
JAMA Cardiol. 2021 Feb 1;6(2):148-158. doi: 10.1001/jamacardio.2020.4511.
2
How artificial kidneys and miniaturized dialysis could save millions of lives.
Nature. 2020 Mar;579(7798):186-188. doi: 10.1038/d41586-020-00671-8.
3
Refining insulin signaling in the proximal tubule at the level of the substrate.
Kidney Int. 2020 Feb;97(2):256-258. doi: 10.1016/j.kint.2019.11.018.
4
Bioengineering strategies for nephrologists: kidney was not built in a day.
Expert Opin Biol Ther. 2020 May;20(5):467-480. doi: 10.1080/14712598.2020.1709439. Epub 2020 Jan 23.
5
Insulin promotes sodium transport but suppresses gluconeogenesis via distinct cellular pathways in human and rat renal proximal tubules.
Kidney Int. 2020 Feb;97(2):316-326. doi: 10.1016/j.kint.2019.08.021. Epub 2019 Sep 5.
6
Relationship Between Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The Battle Continues.
J Clin Med. 2019 Sep 4;8(9):1385. doi: 10.3390/jcm8091385.
7
Toward Portable Artificial Kidneys: The Role of Advanced Microfluidics and Membrane Technologies in Implantable Systems.
IEEE Rev Biomed Eng. 2020;13:261-279. doi: 10.1109/RBME.2019.2933339. Epub 2019 Aug 5.
8
MicroRNA: a novel biomarker and therapeutic target to combat autophagy in diabetic nephropathy.
Eur Rev Med Pharmacol Sci. 2019 Jul;23(14):6257-6263. doi: 10.26355/eurrev_201907_18446.
9
Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.
Bioorg Med Chem Lett. 2019 Jan 15;29(2):317-321. doi: 10.1016/j.bmcl.2018.11.022. Epub 2018 Nov 12.
10
Inflammation in Diabetic Kidney Disease.
Nephron. 2019;143(1):12-16. doi: 10.1159/000493278. Epub 2018 Oct 1.
Zotero 插件